AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01421524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: Up to 10 subjects with relapsed or refractory PCNSL will be enrolled to a PCNSL cohort to evaluate intermittent schedules of CC-122 and to further explore preliminary signals of efficacy and biomarker hypotheses.
Study NCT03270046 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Water enema
Description: Addition of water enema in standard PEG preparation in participants scheduled for CRC screening.
Study NCT04402580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab Biosimilar
Description: for dosage between 100 and 250 mg Rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg Rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg Rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.
Study NCT04138992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DDP
Description: DDP will be used during neoadjuvant and concurrent chemoradiotherapy
Study NCT04138992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDP
Description: DDP will be used during neoadjuvant and concurrent chemoradiotherapy
Study NCT04138992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: used in neoadjuvant chemotherapy
Study NCT04138992 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: standard treatment includes pelvic external beam radiation and brachytherapy
Study NCT04138992 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: standard treatment includes pelvic external beam radiation and brachytherapy
Study NCT02483780 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storytelling
Description: The intervention will center on stories about living with hypertension, with patients speaking in their own words.
Study NCT00973453 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PURETHAL Mites 20,000 AUeq/ml
Description: Group 1: slow regimen (12+2 injections) Initial treatment: incremental weekly dose of 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8, 1.0, 1.2\*, 1.6\* and 2.0\* ml Additional maintenance: 2 two-weekly injections 2.0\* ml~\*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm.
Study NCT00973453 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PURETHAL Mites 20,000 AUeq/ml
Description: Group 2: intermediate regimen (9+2 injections) Initial treatment: incremental weekly dose of 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2\*, 1.6\* and 2.0\* ml.~Additional maintenance: 2 two-weekly injections 2.0\* ml~\*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm.
Study NCT04402580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: 1,200 mg/1,73 sqm orally divided in 2 daily doses
Study NCT02359409 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: goggle balloon
Description: Colonoscopy will be performed using the water immersion technique.
Study NCT02359409 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: water immersion only
Description: Colonoscopy will be performed using a goggle balloon at the tip of the scope with water immersion technique.
Study NCT00973453 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PURETHAL Mites 20,000 AUeq/ml
Description: Group 3: fast initial treatment (6+2 injections) Initial treatment: incremental weekly dose of 0.2, 0.4, 0.8, 1.2\*, 1.6\* and 2.0\*ml.~Additional maintenance: 2 two-weekly injections 2.0\* ml~\*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm.
Study NCT01055561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Participators will be stimulated at specific acupuncture points as determined for the disease by the professional acupuncturists, and acupuncture once a day,last for one week.
Study NCT00934544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 5 mg tablets packaged as 60-count in high-density polyethylene bottles
Study NCT01594320 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H5N1)
Description: Dose A without Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21
Study NCT01594320 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H5N1)
Description: Dose B without Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21
Study NCT01594320 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H5N1); Adjuvant
Description: Dose B with Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21
Study NCT01594320 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H5N1); Adjuvant
Description: Dose C with Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21
Study NCT01594320 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H5N1); Adjuvant
Description: Dose D with Adjuvant 1; intramuscular, deltoid, Day 0 \& Day 21
Study NCT01594320 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Placebo; Intramuscular, deltoid, Day 0 \& Day 21
Study NCT04441411 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NEMOST system
Description: Minimal invasive double rod posterior Non-Fusion Scoliosis Surgery
Study NCT03101566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 IV
Study NCT03101566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 25 mg/m2 IV
Study NCT03101566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1 mg/kg IV
Study NCT03101566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 360 mg or 240 mg IV
Study NCT02314325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADVATE [Antihemophilic Factor (Recombinant)]
Description: In Arm 1 prior patients will be dosed as per body weight 20-40 IU/kg 5-7 infusions per fortnight
Study NCT02314325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADVATE [Antihemophilic Factor (Recombinant)]
Description: In Arm 2 patients who have completed arm 1 will cross over onto an individualised PK tailored alternate day dosing regimen
Study NCT04648813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide monohydrate (Spiriva Respimat)
Description: administered daily, 2 inhalations/5mcg per dose for a total of 8 doses
Study NCT04648813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: administered daily, 2 inhalations per dose for a total of 8 doses
Study NCT01168349 — intervention group
Intervention type: DRUG
Intervention: epoetin beta [NeoRecormon]
Description: As prescribed by physician
Study NCT04354376 — intervention group
Intervention type: DRUG
Intervention: Loop diuretics, thiazides, dihydropyridines
Description: Loop diuretics, thiazides, or dihydropyridines dispensing claim is used as the reference
Study NCT04354376 — intervention group
Intervention type: DRUG
Intervention: Telmisartan
Description: Telmisartan dispensing claim is used as the exposure
Study NCT01757106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Description: general anaesthesia with xenon 50-60% in oxygen (FiO2=0.4-0.5)
Study NCT01757106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: general anesthesia with sevoflurane 1.4% in 50% oxygen/medical air
Study NCT04171531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox® injection
Description: Botulinum toxin A will be prepared by dissolving 100 units of botulinum toxin A into 10 ml of injectable saline. Indigo carmine or methylene blue 0.1 ml will be added to each syringe of botulinum toxin A. The treating physician will inject a total of 10 ml of the Botox A® into approximately 15 to 20 different detrusor muscle sites under direct visualization.
Study NCT04171531 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mid-urethral sling
Description: Mid-urethral Sling Procedure includes retropubic as well as transobturator full length slings. Mini-sling and single-incision sling will not be allowed due to potential risk for higher failure rate.
Study NCT02081157 — intervention group
Intervention type: DEVICE
Intervention: GalaFlex Mesh
Study NCT02577692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: breathing oxygen
Study NCT02577692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambient
Description: breathing ambient air
Study NCT02364141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trunk restraint therapy
Description: Reaching training with trunk restraint by a harness that limited the trunk movements.~Forty-five training minutes, twice a week, totaling twenty sessions, were performed. The training was based in the motor learning concepts including repetitive and task-specific practice. The training task consisted of grasping a cone (3.5 cm diameter base, 13 cm high) and fitting random targets as requested by the therapist in a training platform (54 cm length, 64 cm extent, 1.5 cm high) with 9 targets (6.5 cm diameter) placed 10-13 cm apart, along 3 lines. The targets that were ordered in a way that stimulated the complete range of motion of shoulder and elbow, had pictures, colors, letters and numbers on them yielding variability and feedback to the performing tasks.
Study NCT02364141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trunk unrestraint therapy
Description: Unrestraint reaching training, only with verbal feedback to maintain the trunk right position.~Forty-five training minutes, twice a week, totaling twenty sessions, were performed. The training was based in the motor learning concepts including repetitive and task-specific practice. The training task consisted of grasping a cone (3.5 cm diameter base, 13 cm high) and fitting random targets as requested by the therapist in a training platform (54 cm length, 64 cm extent, 1.5 cm high) with 9 targets (6.5 cm diameter) placed 10-13 cm apart, along 3 lines. The targets that were ordered in a way that stimulated the complete range of motion of shoulder and elbow, had pictures, colors, letters and numbers on them yielding variability and feedback to the performing tasks
Study NCT04085276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001
Description: JS001 240mg, i.v., q3w; Other name: Toripalimab
Study NCT04085276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel 125 mg/m2, i.v., d1, d8, q3w
Study NCT04085276 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, i.v., q3w;
Study NCT04085276 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel 125 mg/m2, i.v., d1, d8, q3w
Study NCT02068326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentalization Based Treatment
Study NCT02068326 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Treatment As Usual
Study NCT04578951 — intervention group
Intervention type: DEVICE
Intervention: FHK® total knee prosthesis
Description: FHK® prosthesis are intended to be implanted in the tibial and femoral regions during total knee arthroplasty in order to restore joint function.
Study NCT00741052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: 12 hourly oral dose of ciprofloxacin for 3 days
Study NCT00741052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 1 gm Azithromycin single dose
Study NCT03242629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral chloral hydrate
Description: Chloral hydrate syrup was available in a concentration of 100 mg×ml-1.The children assigned to receive 0.8 ml×kg-1 of chloral hydrate (80 mg×kg-1) by oral.
Study NCT03242629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enema chloral hydrate
Description: Chloral hydrate syrup was available in a concentration of 100 mg×ml-1 at our hospital.The children assigned to receive 0.8 ml×kg-1 of chloral hydrate (80 mg×kg-1) by enema.
Study NCT01749306 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: ABH001
Description: ABH001 applications topically every 4 weeks (±1 week) with protocol-specified dressings until wound healed or up to 44 weeks
Study NCT00934544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy (BAT)
Description: Prescribing and usage per respective package inserts
Study NCT01749306 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control wound treatment
Description: Control wound care with protocol-specified dressings every 4 weeks (±1 week) up to 20 weeks with optional cross-over to ABH001 for additional 20 weeks
Study NCT01218516 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Farletuzumab
Description: Combination Therapy: Farletuzumab 7.5 mg/kg will be administered intravenously on Cycle 1, Week 1 and Cycle 1, Week 2 (loading dose). Beginning on Cycle 2, Week 1, farletuzumab (7.5 mg/kg) will be administered intravenously on Week 1 of all additional cycles.~Monotherapy: Farletuzumab 7.5 mg/kg will be administered intravenously on Week 1 of every 3-week cycle until disease progression.
Study NCT01218516 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Combination Therapy: Placebo will be administered intravenously on Cycle 1, Week 1 and Cycle 1, Week 2 (loading dose). Beginning on Cycle 2, Week 1, placebo will be administered IV on Week 1 of all additional cycles.~Monotherapy: Placebo will be administered intravenously on Week 1 of every 3-week cycle until disease progression.
Study NCT01218516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered intravenously to achieve area under the serum concentration-time curve of 5 to 6 mg/mL\^min \[AUC5-6\].
Study NCT01218516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered intravenously to achieve area under the serum concentration-time curve of 5 to 6 mg/mL\^min \[AUC5-6\].
Study NCT01218516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m\^2 will be administered intravenously.
Study NCT01218516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m\^2 will be administered intravenously.
Study NCT01218516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m\^2 will be administered intravenously.
Study NCT01218516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m\^2 will be administered intravenously.
Study NCT01218516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2 will be administered intravenously.
Study NCT01218516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2 will be administered intravenously.
Study NCT00696059 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Adalimumab (Humira)
Description: Adalimumab (Humira) 40 mg subcutaneously every other week
Study NCT03571204 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3BNC117 and 10-1074
Description: Both 3BNC117 and 10-1074 administered intravenously at 30 mg/kg dose level in 250 ml normal saline for 8 infusions at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The two antibodies will be mixed in separate bags of saline for sequential administration.
Study NCT00508599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study 2 (48 hours of complete bed rest)
Description: Effects of 48 hours of bed rest on insulin resistance in type 2 diabetic subjects.
Study NCT03904459 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT02178033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Split dose low-volume PEG solution
Description: All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®, Norgine, Harefield, United Kingdom); in the control arm the whole colonoscopy preparation is administered the day before colonoscopy; in the  active comparator  arm one liter of the bowel preparation is administered on the evening before the colonoscopy and the remaining liter on the day of the procedure.
Study NCT02178033 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Split dose low-volume PEG solution
Description: All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®, Norgine, Harefield, United Kingdom); in the control arm the whole colonoscopy preparation is administered the day before colonoscopy; in the  active comparator  arm one liter of the bowel preparation is administered on the evening before the colonoscopy and the remaining liter on the day of the procedure.
Study NCT02643251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine Hydrochloride Topical Gel, 0.1%
Description: Clonidine Gel is supplied as an aqueous gel formulation for topical use.
Study NCT03571204 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3BNC117 and 10-1074
Description: Both 3BNC117 and 10-1074 administered intravenously at 30 mg/kg dose level in 250 ml normal saline for 8 infusions at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The two antibodies will be mixed in separate bags of saline for sequential administration.
Study NCT03571204 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is two separate bags of 250 ml normal saline administered intravenously for 8 infusions at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The two separate bags of placebo are administered sequentially.
Study NCT02643251 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clonidine Hydrochloride Gel Comparator
Description: Clonidine Gel Comparator is supplied as an aqueous gel formulation for topical use.
Study NCT01726010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 22-G Procore Needle
Study NCT02264769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Study NCT03989882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheat germ energy ball
Description: wheat germ mixed other ingredients to make an energy ball
Study NCT03989882 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: corresponding control without wheat germ
Study NCT01722708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: Oral clindamycin 300 Milligrams\*2/Day for a week
Study NCT01722708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Oral metronidazole 500 Milligrams\*2/Day for a week
Study NCT04540419 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular administration
Study NCT04540419 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular administration
Study NCT03047187 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ACLR
Description: * quadriceps and hamstring isometric muscles test~* single hop for distance~* IKDC, KOOS, Tampa and ACL-RSI Questionnaires
Study NCT04383548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyper immunoglobulins containing anti-Corona VS2 immunoglobulin
Description: Prospective randomized clinical study for efficacy of anti-SARS-CoV-2 hyper immunoglobulins prepared from COVID19 convalescent plasma using VIPS Mini-Pool IVIG medical device
Study NCT00584324 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BIS 40
Description: Mini-mental state exam: For subjects > 60, this exam will be administered pre-operatively.~Spielberger State-Trait anxiety test: Spielberger test just before being taken to the operating room.~Spoken word-stem completion test: After discharge from recovery but within 24 hrs. post surgery, this test along with the anxiety test will be administered.~Bispectral Index Monitor: The physiologic monitor is used intraoperatively to assess surgical anesthesia.~Audio File: Playing an audio file (a list of spoken words) via headphones under general anesthesia during the surgical procedure.
Study NCT00584324 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BIS 60
Description: Mini-mental state exam: For subjects > 60, this exam will be administered pre-operatively.~Spielberger State-Trait anxiety test: Spielberger test just before being taken to the operating room.~Spoken word-stem completion test: After discharge from recovery but within 24 hrs. post surgery, this test along with the anxiety test will be administered.~Bispectral Index Monitor: The physiologic monitor is used intraoperatively to assess surgical anesthesia.~Audio File: Playing an audio file (a list of spoken words) via headphones under general anesthesia during the surgical procedure.